Valuation: NovoCure Limited

Market Cap 1.97B 1.7B 1.6B 1.46B 2.74B 189B 2.78B 18.77B 7.34B 94.51B 7.41B 7.25B 314B P/E 2026 *
-13.6x
P/E 2027 * -20.8x
Enterprise Value 1.87B 1.61B 1.52B 1.38B 2.59B 179B 2.64B 17.77B 6.95B 89.46B 7.01B 6.86B 297B EV / Sales 2026 *
2.57x
EV / Sales 2027 * 2.19x
Free-Float
90.04%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 46 01/12/2025
Director of Finance/CFO 52 01/01/2025
Chief Tech/Sci/R&D Officer - 17/01/2023
Director TitleAgeSince
Director/Board Member 59 01/01/2012
Chairman 63 01/01/2009
Director/Board Member 64 05/08/2011
Change 5-day change 1-year change 3-year change Capi.($)
-3.22%+10.54% - - 1.97B
+0.08%+0.73%+29.25%+25.72% 12.88B
+0.08%+1.31%+17.06%+28.98% 6.88B
-0.97%+5.01%+46.63%+41.21% 6.46B
+0.65%+2.81% - - 5.66B
+0.14%+4.47%-25.15%+48.54% 4.56B
-1.67%-3.33%-25.92%-22.81% 3.91B
-2.47%+3.42%+44.50%-45.85% 1.97B
-1.94%+1.08%+61.58%-6.29% 1.71B
-2.80%-11.09%-28.92%+120.76% 1.55B
Average -0.99%+2.13%+14.88%+23.78% 5.06B
Weighted average by Cap. -0.43%+2.06%+18.22%+25.42%

Financials

2026 *2027 *
Net sales 726M 627M 589M 536M 1.01B 69.4B 1.02B 6.9B 2.7B 34.76B 2.73B 2.67B 115B 804M 695M 653M 594M 1.12B 76.92B 1.13B 7.65B 2.99B 38.52B 3.02B 2.95B 128B
Net income -142M -123M -115M -105M -197M -13.58B -200M -1.35B -528M -6.8B -533M -522M -22.6B -84.8M -73.24M -68.82M -62.59M -118M -8.11B -120M -806M -315M -4.06B -318M -311M -13.49B
Net Debt -105M -91.1M -85.61M -77.86M -146M -10.09B -149M -1B -392M -5.05B -396M -387M -16.78B -210M -181M -170M -155M -291M -20.07B -296M -2B -781M -10.05B -788M -771M -33.4B
Logo NovoCure Limited
NovoCure Limited is a global oncology company with a proprietary platform technology called Tumor Treating Fields (TTFields), which are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. The Company's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Its Optune Gio is approved by the FDA under the Premarket Approval pathway for the treatment of adult patients with newly diagnosed glioblastoma together with temozolomide, a chemotherapy drug, and for adult patients with GBM following confirmed recurrence after chemotherapy as monotherapy treatment. Its Optune Lua is approved by the FDA under the PMA pathway for the treatment of adult patients with metastatic non-small cell lung cancer concurrent with PD-1/PD-L1 inhibitors or docetaxel following progression on or after a platinum-based regimen.
Employees
-
Date Price Change
14/08/26 €14.57 -3.22%
13/08/26 €15.05 -0.95%
12/08/26 €15.20 -0.16%
11/08/26 €15.22 +1.10%
10/08/26 €15.06 +6.66%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
16.95USD
Average target price
27.14USD
Spread / Average Target
+60.13%

Quarterly revenue - Rate of surprise